ERAS
Erasca, Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.09
−1.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 1.5M | 3.1M | — | 3.7M | 2.6M |
| Gross Profit | (1.5M) | (3.1M) | — | (3.7M) | (2.6M) |
| Operating Expenses | |||||
| R&D Expense | 108.9M | 92.9M | 115.4M | 103.8M | 112.5M |
| SG&A Expense | 41.8M | 38.6M | 41.7M | 37.7M | 33.0M |
| General & Admin Expense | 41.8M | 38.6M | 41.7M | 37.7M | 33.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 534.0K | (3.1M) | 22.5M | (3.7M) | 99.4M |
| Total Operating Expenses | 151.2M | 128.3M | 179.6M | 137.8M | 244.8M |
| Cost and Expenses | 152.7M | 131.4M | 179.6M | 141.5M | 247.4M |
| Operating Income (EBIT) | (152.7M) | (131.4M) | (179.6M) | (141.5M) | (247.4M) |
| Non-Operating | |||||
| Interest Income | 15.6M | 16.6M | 20.1M | 16.7M | 4.9M |
| Interest Expense | — | — | — | — | 201.4M |
| Net Interest Income | 15.6M | 16.6M | 20.1M | 16.7M | (196.5M) |
| Other Non-Op Income/Expense | (134.5M) | 6.9M | 17.9M | 16.5M | 4.6M |
| Non-Operating Income (excl Interest) | 134.5M | (6.9M) | (22.5M) | (16.5M) | (4.6M) |
| EBT (Pre-Tax Income) | (287.2M) | (124.5M) | (161.7M) | (125.0M) | (242.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (287.2M) | (124.5M) | (161.7M) | (125.0M) | (242.8M) |
| Earnings from Cont. Ops | (287.2M) | (124.5M) | (161.7M) | (125.0M) | (242.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (287.2M) | (124.5M) | (161.7M) | (125.0M) | (242.8M) |
| Per Share | |||||
| Basic EPS | ($0.95) | ($0.44) | ($0.69) | ($0.83) | ($1.99) |
| Diluted EPS | ($0.95) | ($0.44) | ($0.69) | ($0.83) | ($1.99) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 311.3M | 283.5M | 233.8M | 150.2M | 122.0M |
| Diluted Shares Outstanding | 311.3M | 283.5M | 233.8M | 150.2M | 122.0M |
| Profitability Metrics | |||||
| EBITDA | (284.3M) | (121.4M) | (153.3M) | (121.3M) | (240.2M) |
| D&A | 2.9M | 3.1M | 3.8M | 3.7M | 2.6M |
| EBIT | (287.2M) | (124.5M) | (157.1M) | (125.0M) | (242.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026